Given that in the UK Biobank the neuroimaging biomarkers have been collected from a significantly smaller sample size (n ≤ 27 117) than the serum, urine and clinical markers, we may see an association between PCSK9 and biomarkers of dementia or cognitive impairment as the number of participants in the imaging sub‐study increases. This evidence concerns the gene PCSK9 and Cognitive impairment.